Commitments and Contingencies (Details Narrative)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3 Months Ended |
12 Months Ended |
Mar. 20, 2021
USD ($)
|
Jan. 18, 2021
USD ($)
|
Dec. 21, 2020
USD ($)
|
Aug. 12, 2020
USD ($)
shares
|
Aug. 01, 2020
USD ($)
shares
|
Jul. 15, 2020
USD ($)
shares
|
Feb. 18, 2020
USD ($)
|
May 22, 2019
USD ($)
|
Sep. 12, 2018
USD ($)
|
Aug. 20, 2018
USD ($)
|
Apr. 05, 2018
USD ($)
|
Apr. 05, 2018
EUR (€)
|
Apr. 02, 2018 |
Mar. 22, 2018
USD ($)
|
Sep. 14, 2015
USD ($)
|
Dec. 24, 2013
USD ($)
|
Jun. 30, 2020
USD ($)
|
Dec. 31, 2020
USD ($)
shares
|
Dec. 31, 2019
USD ($)
shares
|
Research and development costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,223,676
|
$ 820,906
|
Stock options granted to purchase common stock, issued | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000
|
133,333
|
Stock options grant date fair value |
|
|
|
|
|
|
|
$ 189,060
|
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
NDA Consulting Corp [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Agreement term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 year
|
|
|
|
Consulting and advisory fee |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4,000
|
|
16,000
|
$ 16,000
|
Clinical Trial Research Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
102,944
|
|
Clinical Trial Research Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments for clinical trial |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41,142
|
45,093
|
Aggregate commitments expected |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
616,000
|
|
Collaboration Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
130,882
|
|
Advance amount related to milestone payment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 87,471
|
43,411
|
87,471
|
Collaboration Agreement [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advance amount related to milestone payment |
$ 23,802
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaboration Agreement [Member] | Grupo Espanol de Investigacion en Sarcomas [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Advance amount related to milestone payment |
|
|
|
|
|
|
$ 43,411
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate commitments expected |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,614,000
|
|
Collaboration Agreement [Member] | BioPharmaWorks LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount charges to operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
131,650
|
|
Consulting and advisory fee |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10,000
|
|
|
|
|
Reimbursed expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,650
|
100,000
|
Clinical Trial Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate commitments expected |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,230,000
|
|
Aggregate commitments expected, description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company's aggregate commitments pursuant to the aforementioned clinical trial agreements, less amounts previously paid to date under these agreements, totaled approximately $5,230,000 as of December 31, 2020, consisting of approximately $4,614,000 relating to the GEIS clinical trial and approximately $616,000 relating to the Moffit clinical trial, which are expected to be incurred over the next five years through December 31, 2025.
|
|
Clinical Trial Agreement [Member] | City of Hope [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate commitments expected, description |
|
The Company estimates that from 24 to 30 patients will be needed to complete this clinical trial, at an estimated cost of $2,500,000 to $2,900,000, respectively. If a significant number of patients fail during the dose-escalation process, an increase of up to 12 patients would likely be necessary, at an estimated additional cost of $800,000.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional estimated commitments cost |
|
$ 800,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical Trial Agreement [Member] | City of Hope [Member] | Subsequent Event [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate commitments expected |
|
2,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical Trial Agreement [Member] | City of Hope [Member] | Subsequent Event [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate commitments expected |
|
$ 2,900,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Clinical Agreements [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate commitments expected |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 300,000
|
|
Other Clinical Agreements [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
600,000
|
|
Other Clinical Agreements [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
700,000
|
|
Work Order Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
75,788
|
|
Aggregate commitments expected |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
874,000
|
|
Work Order Agreement [Member] | Theradex Systems, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development costs |
|
|
|
|
|
|
|
|
$ 954,000
|
|
|
|
|
|
|
|
|
18,663
|
51,586
|
Payment expected dividend for pass-through costs, description |
|
|
|
|
|
|
|
|
The clinical trial began in April 2019 and the first patient was entered into the clinical trial in July 2019. At the current rate of accrual, the trial would be completed over a period of four years from its initiation, with the final analysis and reporting expected by July 2023. Costs under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided approximately 94% to Theradex for services and approximately 6% for payments for pass-through costs.
|
|
|
|
|
|
|
|
|
|
|
Material Transfer Agreement [Member] | INSERM [Member] | Maximum [Member] | Development Milestones [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payments |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,750,000
|
|
|
|
|
|
Material Transfer Agreement [Member] | INSERM [Member] | Maximum [Member] | Commercial Milestones [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payments |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 6,500,000
|
|
|
|
|
|
Consulting Agreement with Liberi Life Consultancy BV [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Agreement term |
|
|
|
|
|
|
|
|
|
|
|
|
2 years
|
|
|
|
|
|
|
Payment of a fixed, one-time retainer |
|
|
|
|
|
|
|
|
|
|
$ 18,348
|
|
|
|
|
|
|
|
|
Net payments of sales of products or licensing activities, percentage |
|
|
|
|
|
|
|
|
|
|
2.50%
|
2.50%
|
|
|
|
|
|
|
|
Consulting Agreement with Liberi Life Consultancy BV [Member] | EURO [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payment of a fixed, one-time retainer | € |
|
|
|
|
|
|
|
|
|
|
|
€ 15,000
|
|
|
|
|
|
|
|
Consulting Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount charges to operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,294
|
9,174
|
Unamortized balance of the retainer payment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,174
|
Exclusive License Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount charges to operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 25,001
|
80,669
|
Royalties description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $50,000 in the first four years after sales commence, and $100,000 in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the License Agreement.
|
|
Exclusive License Agreement [Member] | First Four Years [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Minimum payments for royalties |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 50,000
|
|
Exclusive License Agreement [Member] | Five Years and Thereafter [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Minimum payments for royalties |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000
|
|
Exclusive License Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-refundable license issue fee |
|
|
|
|
|
|
|
|
|
$ 25,000
|
|
|
|
|
|
|
|
|
|
Annual license maintenance fee |
|
|
|
|
|
|
|
|
|
25,000
|
|
|
|
|
|
|
|
|
|
Payments on non-refundable milestone |
|
|
|
|
|
|
|
|
|
$ 1,897,000
|
|
|
|
|
|
|
|
|
|
Percentage of milestone |
|
|
|
|
|
|
|
|
|
40.00%
|
|
|
|
|
|
|
|
|
|
Employment Agreement [Member] | General and Administrative Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Charges for salary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
62,500
|
|
Employment Agreement [Member] | Dr. John Kovach [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual salary |
|
|
|
|
|
$ 250,000
|
|
|
|
|
|
|
|
|
|
|
|
45,000
|
60,000
|
Employment Agreement [Member] | Eric Forman [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual salary |
|
|
|
|
|
$ 120,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options granted to purchase common stock, issued | shares |
|
|
|
|
|
350,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employment Agreement [Member] | Eric Forman [Member] | General and Administrative Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Charges for salary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30,000
|
|
Consulting fee |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
38,000
|
48,000
|
Employment Agreement [Member] | Dr. James Miser [Member] | General and Administrative Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Charges for salary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
62,500
|
|
Employment Agreement [Member] | Dr. James Miser [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual salary |
|
|
|
|
$ 150,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options granted to purchase common stock, issued | shares |
|
|
|
|
500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options grant date fair value |
|
|
|
|
$ 143,163
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employment Agreement [Member] | Robert N. Weingarten [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual salary |
|
|
|
$ 120,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options granted to purchase common stock, issued | shares |
|
|
|
350,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options grant date fair value |
|
|
|
$ 100,214
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employment Agreement [Member] | Robert N. Weingarten [Member] | General and Administrative Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Charges for salary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
46,451
|
|
Consulting fee |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 79,995
|
$ 80,380
|
Master Service Agreement [Member] | Foundation for Angelman Syndrome Therapy [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of proceeds agree to pay under agreement |
|
|
|
5.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maximum amount received under agreement |
|
|
|
$ 250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Service Agreement [Member] | IRTH Communications, LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consulting and advisory fee |
|
|
$ 7,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options grant date fair value |
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|